Vitamin A - patients should be advised to limit vitamin A intake to < 15,000 IU /day, to
avoid potential additive effects

DEET - patients who are applying bexatrone should not concurrently use products that
contain DEET  ( N- N -diethyl -m-tolumide ) a common component of insect repellant

CYP-450 system-  concomittant ketoconazole, itraconazole, erythromycin, and grape fruit
could increase baxtrotene  plasma concentration

Cutaneous T cell lymhoma

Adverse reactions-

Cardiovascular -     edema   10%   peripheral edema  5%   

CNS -                         paresthesia   5%

Dermatologic -     contact dermatitis   12%  exfoliative dermatitis   5%   pruritus  35%
                                rash    65%    maculopapular rash   5%   skin disorder   25%
                                sweating    5%  

Hematologic/ Lymphatic -    leukopenia   5%    lymphadenopathy   5%  

                                WBC abnormal  5%

Metabolic/nutrional -      hyperlipedmia   8% 

Respiratory -                  cough increased    5%     pharynigitis         5%

Miscellaneous -        asthenia   5%    headache  12%   infection   15%    pain  25% 

Hypersensitivity

Special precaution-

Renal function impairment -  no formal studies have been conducted with bexaotene in
patients with renal insufficiency. Renal insufficency can result in significant protein binding
changes. Pharmacokinetics may be altered in patients with renal insufficency

Hepatic function impairment -  no specific studies have been conducted in patients with
hepatic insuficiency. Hepatic impairment would be expected to lead to greatly decreased
clearance

Special risk - bexatrone should be used with caution in patients with known hypersensitivity
to other retinoids

Photosensitivity - patients should be advised to to minimize exposure to sunlight and artificial light during the use of bexarotene

Pregnancy -  bexarotene 1% may harm fetal harm when administered to pregnant woman.
Bexarotene should not b egiven to a pregnant woman ror to a woman who intends to
become pregnant. If a woman becomes pregnant while taking bexarotene , bexarotene
must be stopped immediately

Lactation- Not known whether bexarotene is xcreated in human milk.
Decision should be taken whether to discontinue nursing or discontinue the
drug depending on the importance of drug to the mother.

Children - safety and efficacy in pediatric patients have not been estblished

Elderly- No overall differnces in safety were observed between patients > 65 years
and younger patients, but greater sensitivity to bexarotene can not be ruled out

Indication-

Cutaneous T cell lymhoma

Dosage-
Baxatrone should be initially applied once every  day for the first week.
Increase the application frequency at weekly intervals to once daily, then twice daily
then 3 times daily, and finally 4 times daily according to individual lesion tolerance.

Do not use occlusive dressings with bexarotene

1. Photosensitivity - patients should be advised to to minimize exposure to sunlight and artificial light during the use of bexarotene

2. Do not use occlusive dressings with bexarotene

Take with food

Pregnancy - 
Bexarotene 1% may harm fetal harm when administered to pregnant woman.
Bexarotene should not b egiven to a pregnant woman ror to a woman who intends to
become pregnant. If a woman becomes pregnant while taking bexarotene , bexarotene
must be stopped immediately

Lactation-
Not known whether bexarotene is xcreated in human milk.
Decision should be taken whether to discontinue nursing or discontinue the
drug depending on the importance of drug to the mother.

Children -
Safety and efficacy in pediatric patients have not been estblished

Elderly-
No overall differnces in safety were observed between patients > 65 years
and younger patients, but greater sensitivity to bexarotene can not be ruled out